nach oben

Familial Cancer

Erschienen in:

04.12.2017 | Editorial

The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer

verfasst von: Hans F. A. Vasen

Erschienen in: Familial Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In this issue of Familial Cancer, Barnes et al. describe a screening program for individuals at high risk of developing pancreatic ductal adenocarcinoma (PDAC) [1]. Approximately 3–10% of all patients with PDAC have a positive family history for this cancer [2], and 4% have an underlying gene defect, with ATM, BRCA1 & BRCA2, and PALB2 being the most commonly effected genes [3‐6] (Table 1). Familial pancreatic cancer (FPC) is defined by the occurrence of PDAC in two or more first-degree relatives, in the absence of an underlying gene defect [2]. The risk of developing PDAC depends on the particular gene defect (Table 1) [7‐12], and in FPC, on the number of first-degree family members with PDAC. …

Barnes CA, Krzywda E, Lahiff S, McDowell D, Christians KK, Knechtges P et al (2017) Development of a high risk pancreatic screening clinic using 3.0 T MRI. Fam Cancer. https://doi.org/10.1007/s10689-017-0057-z.PubMed

Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453CrossRefPubMed

Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A et al (2017) Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 35(30):3382–3390CrossRefPubMed

Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG et al (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17(7):569–577CrossRefPubMed

Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166–175CrossRefPubMed

Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J et al (2017) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. https://doi.org/10.1038/gim.2017.85 PubMed

de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA et al (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14(21):7151–7157CrossRefPubMed

Thompson D, Easton DF, Breast Cancer Linkage C (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365CrossRefPubMed

van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719CrossRefPubMedPubMedCentral

10.

Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D et al (2017) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. https://doi.org/10.1136/gutjnl-2017-314057

11.

Breast Cancer Linkage C (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15):1310–1316CrossRef

12.

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol 34(17):2010–2019CrossRefPubMed

13.

Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131(4):247–255CrossRefPubMed

14.

Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804 (quiz e14-5)CrossRefPubMedPubMedCentral

15.

Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58(10):1410–1418CrossRefPubMed

16.

Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783CrossRefPubMed

17.

Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347CrossRefPubMed

18.

Harinck F, Konings IC, Kluijt I, Poley JW, van Hooft JE, van Dullemen HM et al (2016) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 65(9):1505–1513CrossRefPubMed

19.

Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC et al (2015) Screening for pancreatic adenocarcinoma in BRCA2 mutation carriers: results of a disease simulation model. EBioMedicine 2(12):1980–1986CrossRefPubMedPubMedCentral

Titel: The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer
verfasst von: Hans F. A. Vasen
Publikationsdatum: 04.12.2017
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 1/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-0066-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing

TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma

A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting

How do clinical genetics consent forms address the familial approach to confidentiality and incidental findings? A mixed-methods study

Next generation sequencing is informing phenotype: a TP53 example

Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie